News | August 04, 2009

MDS Nordion Says MAPLE Reactors Could Solve the Isotope Crisis

August 4, 2009 - MDS Nordion, a leading provider of medical isotopes and radiopharmaceuticals, has submitted a proposal to Canada’s Expert Review Panel on Medical Isotope and Technetium-99m (Tc-99m) Generator Production, stating the best answer to the shortage of medical radioisotopes is the completion and bringing into service of the MAPLE project.

With no domestic or international sources of supply that can fully mitigate the current global shortage of medical isotopes, MDS Nordion urges Atomic Energy of Canada Limited (AECL) to complete the MAPLE project to address this shortage. With expertise and guidance from the South African Nuclear Energy Corp. (Necsa), owner and operator of the SAFARI-1 reactor, and working with AECL, MDS Nordion believes a solution could be achieved in an estimated 24 months.

MDS Nordion urges AECL to honor its long-standing commitment to replace the National Research Universal (NRU) by bringing the MAPLE facilities into service. This company says it can be done through AECL collaborating with Necsa on the adaption of the OSCAR computer codes, which are successfully used by the world’s leading isotope producing reactors. The computer codes are specifically designed to model research reactor performance and operation and are being used by the High Flux Reactor in Petten, Netherlands, and SAFARI-1, in South Africa. MDS Nordion says adopting the OSCAR computer codes could be essential to resolving the existing discrepancy between the predicted and measured value of the power coefficient of reactivity of the MAPLE reactors allowing them to be licensed by the Canadian Nuclear Safety Commission (CNSC) for safe operation.

In addition to the OSCAR computer codes, MDS Nordion is proposing the construction of a fully licensed production facility to manufacture Tc-99m generators for distribution to Canadian hospitals in all regions of Canada and abroad. MDS Nordion said it will build, operate and maintain the generator production line, and perform all necessary activities; including provision of licensed packaging, consumable supplies and facilitate transport logistics to all Canadian healthcare centers.

For more information: www.mdsnordion.com

Related Content

NorthStar Medical Radioisotopes Completes Construction on Beloit, Wis. Molybdenum-99 Processing Facility
News | Radiopharmaceuticals and Tracers | July 16, 2019
NorthStar Medical Radioisotopes LLC  announced completion of construction on its 20,000-square-foot molybdenum-99 (Mo-...
BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility
News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) — the voice of the radionuclide, radiopharmaceutical...
Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 26, 2018 | Dave Fornell
February 8, 2018 — The U.S.
ARTMS Products Inc. and GE Healthcare Team Up to Expand Cyclotron-Produced Radioisotopes
News | Radiopharmaceuticals and Tracers | August 30, 2017
ARTMS Products Inc. signed a strategic partnership with GE Healthcare around ARTMS’ proprietary QUANTM99 Irradiation...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a...
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the development of a new...
University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes
News | Radiopharmaceuticals and Tracers | April 13, 2017
The University of Missouri Research Reactor (MURR) and its partners Nordion and General Atomics (GA), announced in...
Overlay Init